EASL - The Digital International Liver Congress™

August 27 - 29 |

Digital Conference

00 days 00 hours 00 minutes 00 seconds
Book a virtual meeting

Every year, scientific and medical experts from a broad range of fields including hepatology, gastroenterology, internal medicine, cell biology, transplant surgery, infectious diseases, microbiology, virology, pharmacology, pathology, radiology, and imaging, come together from around the world at the International Liver Congress™ to learn about the latest in liver research. This year, owing to COVID-19 disruptions, the event is being held entirely online, as The Digital International Liver Congress™ 2020.

Below you will find intro videos for our products, a number of resource materials, a list of all of this year's abstracts that will be displayed at ILC2020 and of course our lovely team, who are available for virtual meetings where you can ask any questions you may have, or just get to know us a little better.

 


Get to know our products

 

 

                                                         

 

Resources

 

Below you can find links to download all of our key resources that would be available to you if you were to visit our exhibition booth. If you have any questions or would like a specific resource, that you're unable to find below, please get in touch.

 

LiverMultiScan

MRCP+

Pharma Solutions

Company Overview

Download

Download

Download

Download

Book a Virtual Meeting

If you'd like more information on Perspectum or a specific product, please get in touch and book a virtual meeting with one of our team

Accepted Abstracts

THU483

Quantitative magnetic resonance imaging predicts individual future liver performance after liver resection for cancer.

The future liver performance (FLP) of an individual undergoing surgical liver resection to remove cancer is critical for their survival and recovery. We report the development and clinical testing of a novel magnetic resonance image (MRI) post-processing tool that combines quantitative multiparametric MRI with anatomical liver segmentation to estimate FLP. This is intended to inform the assessment of individualised operative risk and augment patient and surgeon decision making prior to liver resection.

FRI024

Investigation of a composite imaging biomarker for identification of NASH patients in a Japanese population.

NASH pathogenesis is complex and composite biomarkers can improve identification of patients who are at risk of poor clinical outcomes. LiverMultiScan® uses multiparametric MRI to measure proton density fat fraction (PDFF) and iron-corrected T1 (cT1). PDFF quantifies hepatic steatosis while cT1 correlates with key histopathological features of NASH – ballooning, inflammation and fibrosis, and predicts clinical outcomes in patients with chronic liver disease. Herein, we report the performance of cT1 and PDFF in composite with non-imaging biomarkers, for the stratification of patients with suspected NASH in a prospective Japanese study cohort.

SAT253

Multiparametric MRI of liver and spleen is a reliable non-invasive predictor of clinically relevant hepatic venous pressure gradient thresholds and predicts failure of primary prophylaxis for variceal bleeding.

Multiparametric MRI (mpMRI) of the liver and spleen is a promising modality for non-invasive assessment of portal hypertension, offering a potential alternative to hepatic venous pressure gradient (HVPG) measurement, which is invasive and not widely available. Clinically relevant HVPG thresholds include (i) HVPG≥10mmHg, which defines clinically significant portal hypertension (CSPH) and predicts decompensation, (ii) HVPG>12mmHg, which predicts increased risk of variceal bleeding, and (iii) HVPG>16mmHg, which is associated with increased mortality. This study aims to evaluate the reliability of mpMRI of liver and spleen to predict clinically relevant HVPG thresholds (HVPG≥10mmHg, HVPG>12mmHg, HVPG>16mmHg) and development of variceal bleeding in a cohort of patients with chronic liver disease.

SAT256

Evolving imaging in biliary disease: quantitative magnetic resonance cholangiopancreatography findings correlate with the modified Amsterdam score in patients with primary sclerosing cholangitis.

Quantitative magnetic resonance cholangiopancreatography (MRCP+) is a novel non-invasive imaging technique for quantifying biliary tree volume, duct diameters, and dilated/strictured regions in hepatobiliary disease. It is designed to address the limitations of traditional MRCP interpretation which can have large inter-observer variations. The aim of this study is to investigate the utility of quantitative MRCP in a prospective study of patients with primary sclerosing cholangitis (PSC) and evaluate its correlation with the modified Amsterdam cholangiography score.

SAT271

Quantitative Magnetic Resonance Cholangiopancreatography imaging in patients with PSC - Feasibility and Preliminary Analysis for Prediction of Clinical Outcomes.

Magnetic resonance cholangiopancreatography (MRCP) is a non-invasive imaging technique commonly used for the evaluation of biliary disease. Despite its widespread use, MRCP relies on subjective assessments, lacking robust quantitative metrics and cannot predict the onset of liver related events. Quantitative MRCP (MRCP+TM) is a novel technique that can quantitively assess biliary tree metrics. This study sought to understand the utility of MRCP+ in predicting clinical outcomes for primary sclerosing cholangitis (PSC).